Bora Pharmaceuticals: Transforming Taiwan's Biotech Landscape｜Taiwan Talks

How does the presence of Contract Development and Manufacturing Organizations (CDMOs) impact Taiwan's pharmaceutical sector? In this episode of TaiwanTalks, Bora Pharmaceuticals CEO Bobby Sheng shares his expertise of the worldwide pharmaceutical CDMO market. He illuminates the biotech landscape and crucial role Taiwan plays in this system.
Our guests are:
Bobby Sheng
Chair and CEO, Bora Pharmaceuticals
Chapters
01:48 - Navigating CDMO Selection and Taiwan's Role
06:30 - Bora's Genesis: Scaling, Scope and Strategic Growth
15:14 - Shaping Market Perceptions: Bora's Growth Trajectory
18:07 - Pandemic Impact: Bora's Manufacturing Resilience
20:55 - Asia's CDMO Landscape and Taiwan's Stand
24:39 - Overcoming Obstacles: CDMO's Path to TSMC-Like Success
29:50 - People Power: Bora's Winning Strategy and Company Culture
37:58 - Owner Operators: Bora's Expansion into GSK Canada
41:15 - Bora’s Taiwan Tribute: Entrepreneurship and Mentorship